Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Advair

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    GSK shares promising phase 3 results for linerixibat in PBC-related itch

    Pruritus is experienced by up to 90% of patients with the rare liver disease

    Genesis Research Group A&P image

    Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

    In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...

    Genesis Research Group

    - PMLiVE

    GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

    Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

    - PMLiVE

    GSK’s five-in-one meningococcal vaccine recommended by CDC advisory committee

    Penmenvy combines the antigenic components of GSK's approved Bexsero and Menveo vaccines

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

    Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links